74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
UroGen Pharma Ltd
Open
11.01 1.01
Overview
Share price change
24h
Min
10.39
Max
11.26
Income | -14M -38M |
|---|---|
Sales | -639K 25M |
EPS | -0.8 |
Profit margin | -152.705 |
Employees | 235 |
EBITDA | -16M -31M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +270.65% upside |
Next Earnings | 12 May 2025 |
|---|
Market Cap | 130M 549M |
|---|---|
Previous open | 10 |
Previous close | 11.01 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
UroGen Pharma Ltd Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
UroGen Pharma Ltd Forecast
Price Target
By TipRanks
270.65% upside
12 Months Forecast
Average 39.4 USD 270.65%
High 55 USD
Low 31 USD
Based on 5 Wall Street analysts offering 12 month price targets forUroGen Pharma Ltd - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
